The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy

Molecular Oncology

Johannes C. van derMijn¹  Lorraine J. Gudas¹  Clara Oromendia¹  Juan Miguel Mosquera²  Alexandros Sigaras²  Scott T. Tagawa²  Olivier Elemento²  Kenneth W. Eng²  Pooja Chandra²  Bishoy F. Faltas²  David M. Nanus²  Sinan Ramazanoglu²  Evan Fernandez²  Cora N. Sternberg²  Ana M. Molina²  Himisha Beltran²  Andrea Sboner² 

[1] Department of Pharmacology Weill Cornell Medicine New York NY USA;Englander Institute for Precision Medicine Weill Cornell Medicine New York NY USA;

关键词: cancer;    genomics;    immunotherapy;    kidney;    metastasis;    VEGF;   

DOI  :  10.1002/1878-0261.13204

来源: DOAJ

【 摘 要 】

Primary clear cell renal cell carcinoma (ccRCC) has been previously characterized, but the genomic landscape of metastatic ccRCC is largely unexplored. Here, we performed whole exome sequencing (WES) in 68 samples from 44 patients with ccRCC, including 52 samples from a metastatic site. SETD2, PBRM1, APC and VHL were the most frequently mutated genes in the metastatic ccRCC cohort. RBM10 and FBXW7 were also among the 10 most frequently mutated genes in metastatic tissues. Recurrent somatic copy number variations (CNV) were observed at the previously identified regions 3p25, 9p21 and 14q25, but also at 6p21 (CDKN1A) and 13q14 (RB1). No statistically significant differences were found between samples from therapy‐naïve and pretreated patients. Clonal evolution analyses with multiple samples from 13 patients suggested that early appearance of CNVs at 3p25, 9p21 and 14q25 may be associated with rapid clinical progression. Overall, the genomic landscapes of primary and metastatic ccRCC seem to share frequent CNVs at 3p25, 9p21 and 14q25. Future work will clarify the implication of RBM10 and FBXW7 mutations and 6p21 and 13q14 CNVs in metastatic ccRCC.

【 授权许可】

Unknown